Data as of Oct 17
| +0.28 / +0.23%|
The 14 analysts offering 12-month price forecasts for United Therapeutics Corp have a median target of 105.00, with a high estimate of 165.00 and a low estimate of 79.00. The median estimate represents a -15.77% decrease from the last price of 124.66.
The current consensus among 15 polled investment analysts is to Buy stock in United Therapeutics Corp. This rating has held steady since October, when it was upgraded from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.